WHAT TYPE OF CRO IS REDOXIS?

Redoxis is a specialized preclinical contract research organization focused on inflammation, immunology and immune-mediated diseases. The company provides tailored in vitro, ex vivo, in vivo and high-resolution biology services from Lund, Sweden.

WHICH DISEASE MODELS DOES REDOXIS OFFER?

Redoxis provides models and experimental approaches for rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, psoriatic arthritis, atopic dermatitis, acute inflammation, anti-GBM nephritis, Guillain-Barré syndrome and other inflammation-related conditions.

CAN REDOXIS COMBINE IN VITRO AND IN VIVO STUDIES?

Yes. Redoxis can combine in vitro and ex vivo assays, in vivo disease models, biomarker analysis, immune profiling, histology and advanced tissue analysis within one integrated project.

DOES REDOXIS DEVELOP TAILORED STUDIES?

Yes. Studies are designed around the therapeutic modality, mechanism of action, biological question and development stage. Established models can be adapted, and new experimental approaches can be developed when required.

WHICH THERAPEUTIC MODALITIES CAN REDOXIS EVALUATE?

Redoxis works with different therapeutic modalities, including small molecules, antibodies, biologics, cell-based approaches and other emerging therapies. The study strategy is adapted to the specific mechanism and translational question.

WHERE IS REDOXIS LOCATED?

Redoxis is located at Medicon Village in Lund, Sweden, within the life-science cluster of the Greater Copenhagen region.

HOW CAN I DISCUSS A PRECLINICAL PROGRAM WITH REDOXIS?

Contact Redoxis with a brief description of the therapeutic modality, target, indication and current development stage. A scientist will help assess relevant models, assays and study strategies.